Re-emergence of a tumefactive demyelinating lesion after initiation of fingolimod therapy

J Neurol Sci. 2017 Aug 15:379:167-168. doi: 10.1016/j.jns.2017.06.002. Epub 2017 Jun 7.

Authors

Yu Hashimoto¹, Koji Shinoda¹, Eizo Tanaka¹, Taira Uehara¹, Takuya Matsushita¹, Ryo Yamasaki¹, Jun-Ichi Kira²

Affiliations

¹ Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
² Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Electronic address: [email protected].

PMID: 28716234
DOI: 10.1016/j.jns.2017.06.002

No abstract available

Keywords: Fingolimod; MRI; Multiple sclerosis; Tumefactive demyelinating lesion.

Publication types

Case Reports
Letter

MeSH terms

Demyelinating Diseases / chemically induced*
Demyelinating Diseases / complications
Demyelinating Diseases / diagnostic imaging
Female
Fingolimod Hydrochloride / administration & dosage*
Fingolimod Hydrochloride / adverse effects*
Humans
Magnetic Resonance Imaging
Middle Aged
Multiple Sclerosis / complications
Multiple Sclerosis / diagnostic imaging
Neuroimaging

Substances

Fingolimod Hydrochloride